Host antitumor immunity plays a role in the survival of patients with newly diagnosed triple-negative breast cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

27 citing papers in PubMed.

1. Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.The Lancet. Oncology · 2017
   Trial
2. Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer.Investigational new drugs · 2016
   Trial
3. Peripheral Blood Transcriptome in Breast Cancer Patients as a Source of Less Invasive Immune Biomarkers for Personalized Medicine, and Implications for Triple Negative Breast Cancer.Cancers · 2022
   Review
4. Predicting therapeutic efficacy of endocrine therapy for stage IV breast cancer by tumor-infiltrating lymphocytes.Molecular and clinical oncology · 2020
   Article
5. Programmed cell death-ligand 1 expression in stromal immune cells is a marker of breast cancer outcome.Journal of Cancer · 2020
   Article
6. Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer.NPJ breast cancer · 2020
   Article
7. Immunologic cellular characteristics of the tumour microenvironment of hepatocellular carcinoma drive patient outcomes.World journal of surgical oncology · 2019
   Article
8. Correlation of CD8+ Expression, Foxp3+ Expression, and CD8+/Foxp3+ Ratio with Triple Negative Breast Cancer Stage in Sanglah General Hospital.Open access Macedonian journal of medical sciences · 2019
   Article
9. Multiplex immunohistochemistry accurately defines the immune context of metastatic melanoma.Scientific reports · 2018
   Article
10. Neutrophil-lymphocyte ratio predicts response to chemotherapy in triple-negative breast cancer.Current oncology (Toronto, Ont.) · 2018
    Article
11. Emerging Opportunities of Radiotherapy Combined With Immunotherapy in the Era of Breast Cancer Heterogeneity.Frontiers in oncology · 2018
    Review
12. Increased Tumour Infiltration of CD4+ and CD8+ T-Lymphocytes in Patients with Triple Negative Breast Cancer Suggests Susceptibility to Immune TherapyAsian Pacific journal of cancer prevention : APJCP · 2017
    Article
13. High PD-L1 Expression Is Closely Associated With Tumor-Infiltrating Lymphocytes and Leads to Good Clinical Outcomes in Chinese Triple Negative Breast Cancer Patients.International journal of biological sciences · 2017
    Article
14. Expression of the MHC class II in triple-negative breast cancer is associated with tumor-infiltrating lymphocytes and interferon signaling.PloS one · 2017
    Article
15. An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers.Breast cancer research : BCR · 2016
    Article
16. Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients.Cancer science · 2016
    Article
17. Towards tumor immunodiagnostics.Annals of translational medicine · 2016
    Review
18. Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies.Journal of translational medicine · 2016
    Article
19. Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating Lymphocytes.Cancer immunology research · 2016
    Article
20. Clinical relevance of host immunity in breast cancer: from TILs to the clinic.Nature reviews. Clinical oncology · 2016
    Review

Corrections and comments

• Commented on by
  Reply to A. Ocaña et al and P.G. Tsoutsou et al.2015
• Comment on
  Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.2014

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as